Literature DB >> 1973830

Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

M F Press1, C Cordon-Cardo, D J Slamon.   

Abstract

The HER-2/neu proto-oncogene is homologous with, but distinct from, the epidermal growth factor receptor. Current evidence indicates that this gene is frequently amplified and/or overexpressed in some human breast and ovarian cancers and that these alterations may be clinically important; however, little is known about the expression pattern of the gene in normal tissues. Using immunohistochemistry and northern blot analyses to identify the HER-2/neu protein and transcript respectively, we have evaluated a variety of normal adult and fetal tissues for HER-2/neu expression. HER-2/neu protein was identified on cell membranes of epithelial cells in the gastro-intestinal, respiratory, reproductive, and urinary tract as well as in the skin, breast and placenta. Northern hybridization confirmed the presence of the 4.5 kb transcript encoding the protein in these tissues. The amount of HER-2/neu message and protein was generally higher in fetal tissues than in the corresponding normal adult tissues. HER-2/neu expression levels in these normal tissues were similar to the levels found in non-amplified, non-overexpressing breast cancers and breast cancer cell lines. Southern hybridization of extracted DNA showed that none of the normal tissues expressing HER-2/neu had amplification of the gene. These results confirm that HER-2/neu is normally a membrane constituent of a variety of epithelial cell types.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973830

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  146 in total

1.  High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production.

Authors:  Jonathan N Thon; Matthew T Devine; Antonija Jurak Begonja; Jay Tibbitts; Joseph E Italiano
Journal:  Blood       Date:  2012-06-04       Impact factor: 22.113

2.  Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.

Authors:  Diane E Milenic; Karen J Wong; Kwamena E Baidoo; Tapan K Nayak; Celeste A S Regino; Kayhan Garmestani; Martin W Brechbiel
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

3.  Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains.

Authors:  R Murali; P J Brennan; T Kieber-Emmons; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

4.  Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas.

Authors:  B S Chozick; D L Benzil; E G Stopa; J C Pezzullo; N W Knuckey; M H Epstein; S D Finkelstein; P W Finch
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

5.  Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration.

Authors:  Jashodeep Datta; Cinthia Rosemblit; Erik Berk; Lori Showalter; Prachi Namjoshi; Rosemarie Mick; Kathreen P Lee; Andrew M Brod; Rachel L Yang; Rachel R Kelz; Elizabeth Fitzpatrick; Clifford Hoyt; Michael D Feldman; Paul J Zhang; Shuwen Xu; Gary K Koski; Brian J Czerniecki
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

6.  Development of anti-p185HER2 immunoliposomes for cancer therapy.

Authors:  J W Park; K Hong; P Carter; H Asgari; L Y Guo; G A Keller; C Wirth; R Shalaby; C Kotts; W I Wood
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

7.  Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.

Authors:  Jean-François Mineo; Anne Bordron; Marc Baroncini; Claude-Alain Maurage; Carole Ramirez; Rose-Mary Siminski; Christian Berthou; Phong Dam Hieu
Journal:  J Neurooncol       Date:  2007-06-15       Impact factor: 4.130

Review 8.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

9.  Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma.

Authors:  P A van Dam; I B Vergote; D G Lowe; J V Watson; P van Damme; J C van der Auwera; J H Shepherd
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

10.  Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors.

Authors:  J Carlsson; L Shen; J Xiang; J Xu; Q Wei
Journal:  Oncol Lett       Date:  2012-10-25       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.